logo
logo

Harbour BioMed Raises $75 Million Series B+ Venture Capital Financing to Accelerate Its Innovative Pipeline

Mar 12, 2020•over 5 years ago

Amount Raised

$75 Million

Round Type

series b

CambridgeBiotechnology

Description

Harbour BioMed (HBM) today announced successful completion of its Series B+ round financing of $75 million to accelerate the advancement of its clinical-stage compounds and growing portfolio of next generation biotherapeutics for treating cancer and immunological diseases. New investors participating in the financing – SK Holdings, Greater Bay Area Fund, Efung Capital, Zheshang Venture Capital and Zhejiang University Future Capital and JT New Century - joined existing investors, including Legend Capital, AdvanTech and GIC Pvt. Ltd. The company previously completed an $85 million Series B financing in August 2018.

Company Information

Company

Harbour BioMed

Location

Cambridge, Massachusetts, United States

About

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People